SPI
17.342,35
PKT
+88,43
PKT
+0,51
%
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 18.07.14 | Roche Conviction Buy | Goldman Sachs Group Inc. | |
| 18.07.14 | BB Biotech buy | equinet AG | |
| 17.07.14 | Roche buy | UBS AG | |
| 17.07.14 | UBS buy | UBS AG | |
| 17.07.14 | Roche overweight | Morgan Stanley | |
| 17.07.14 | Novartis buy | S&P Capital IQ | |
| 17.07.14 | Nestlé overweight | JP Morgan Chase & Co. | |
| 17.07.14 | Holcim buy | UBS AG | |
| 17.07.14 | Holcim buy | UBS AG | |
| 16.07.14 | Givaudan buy | Nomura | |
| 15.07.14 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.07.14 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 14.07.14 | Novartis buy | UBS AG | |
| 14.07.14 | UBS buy | Deutsche Bank AG | |
| 14.07.14 | UBS buy | Deutsche Bank AG | |
| 14.07.14 | Novartis buy | Jefferies & Company Inc. | |
| 14.07.14 | Novartis buy | Jefferies & Company Inc. | |
| 14.07.14 | UBS overweight | HSBC | |
| 11.07.14 | Nestlé buy | Citigroup Corp. | |
| 11.07.14 | Holcim Outperform | BNP PARIBAS | |
| 11.07.14 | Holcim Outperform | BNP PARIBAS | |
| 09.07.14 | UBS Underweight | JP Morgan Chase & Co. | |
| 09.07.14 | UBS overweight | JP Morgan Chase & Co. | |
| 09.07.14 | Roche kaufen | Independent Research GmbH | |
| 09.07.14 | Nestlé overweight | Morgan Stanley | |
| 08.07.14 | Holcim buy | UBS AG | |
| 08.07.14 | Holcim buy | UBS AG | |
| 08.07.14 | Holcim overweight | JP Morgan Chase & Co. | |
| 08.07.14 | Holcim overweight | JP Morgan Chase & Co. | |
| 08.07.14 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 08.07.14 | ABB (Asea Brown Boveri) Neutral | Merrill Lynch & Co., Inc. | |
| 08.07.14 | Holcim buy | Deutsche Bank AG | |
| 08.07.14 | ABB (Asea Brown Boveri) Sell | Goldman Sachs Group Inc. | |
| 07.07.14 | Givaudan Neutral | Citigroup Corp. | |
| 07.07.14 | Novartis overweight | JP Morgan Chase & Co. | |
| 07.07.14 | Swiss Re overweight | Morgan Stanley | |
| 07.07.14 | Swiss Re Underweight | JP Morgan Chase & Co. | |
| 07.07.14 | Roche overweight | JP Morgan Chase & Co. | |
| 07.07.14 | Novartis Neutral | Merrill Lynch & Co., Inc. | |
| 07.07.14 | Swiss Re Neutral | Goldman Sachs Group Inc. |